Data mining of the expression and regulatory role of BCAT1 in hepatocellular carcinoma

HAIFAN ZOU1,2*, MINJUN LIAO1,3*, WENTAO XU1, RENZHI YAO1 and WEIJIA LIAO1

1Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University; 2Scientific Experiment Center, Guilin Medical University, Guilin, Guangxi 541001; 3Clinical School of Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China

Received May 10, 2019; Accepted September 6, 2019

DOI: 10.3892/ol.2019.10932

Abstract. Branched chain amino acid transaminase 1 (BCAT1) catalyzes the production of glutamates and branched-chain α-ketoacids from branched chain amino acids, and a normal BCAT1 expression is associated with tumorigenesis. Sequencing data from public databases, including The Cancer Genome Atlas, was used to analyze BCAT1 expression and regulation networks for hepatocellular carcinoma (HCC). Expression and methylation were assessed using UALCAN analysis, and data from multiple datasets concerning the BCAT1 expression level and associated survival rates were further analyzed using HCCDB; interaction networks of biological function were constructed using GeneMANIA. LinkedOmics was used to indicate correlations between BCAT1 and any identified differentially expressed genes. Gene enrichment analysis of BCAT1-associated genes was conducted using the Web-based Gene SeT AnaLysis Toolkit. The expression levels of BCAT1 were increased in patients with HCC and in most cases, the level of BCAT1 promoter methylation was reduced. Interaction network analysis suggested that BCAT1 was involved in ‘metabolism’, ‘carcinogenesis’ and the ‘immune response’ via numerous cancer-associated pathways. The present study revealed the expression patterns and potential function networks of BCAT1 in HCC, providing insights for future research into the role of BCAT1 in hepatocarcinogenesis. In addition, the study provided researchers with a way to analyze the genes of interest so they can continue their research in the right direction.

Introduction

With the sixth highest incidence and fourth highest mortality rates, liver cancer is one of the most important causes of cancer-associated mortality worldwide. In 2018, ~840,000 cases of liver cancer were diagnosed in addition to 782,000 mortalities, of which ≥85% were associated with hepatocellular carcinoma (HCC) (1,2). Although the development of predictive and treatment methods has increased the survival rates of patients with HCC, the early diagnosis and 5-year survival rates remain poor (2). Clinically, HCC can be diagnosed or prognosed using ultrasound, computerized tomography and the detection of serum α-fetoprotein (AFP) levels (3). However, the sensitivity and specificity of these methods is unsatisfactory. The complexity of the molecular mechanisms of HCC has prevented the elucidation of its development and therefore, the means with which to successfully treat the disease. Thus, it is necessary to identify novel therapeutics and drug targets by screening HCC-associated gene networks.

Branched chain amino acid transaminase 1 (BCAT1) is able to catalyze the synthesis of α-ketoglutarates from branched chain amino acids (BCAAs) and the subsequent production of glutamates and branched-chain α-ketoacids. BCAT1 is reportedly involved in the progression of various malignancies, including breast (4), ovarian (5), gastric (6) and pancreatic cancer (7), as well as HCC (8,9). The overexpression of BCAT1 promoted cellular proliferation, migration and invasion in various types of tumor via multiple signaling pathways (10,11). In addition, previous studies have revealed that BCAT1 is involved in DNA methylation and associated with inflammatory diseases (12,13). However, one study has suggested that BCAT1 expression is not associated with the overall survival of patients with HCC (14), thus its exact role and mechanism in hepatocarcinogenesis remain controversial.

In a previous study, BCAT1 expression levels were upregulated in the corresponding HCC tissues. Thus, to further investigate the role of BCAT1 in HCC, patient data from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets (https://www.ncbi.nlm.nih.gov/gds) was used to assess the expression levels of BCAT1 in patients with HCC. Functional networks of BCAT1 in HCC were also analyzed. The results revealed that BCAT1
may represent a novel therapeutic and drug target for HCC, which may provide insights for future research and the development of treatment strategies.

Materials and methods

UALCAN analysis. UALCAN (http://ualcan.path.uab.edu) is a publicly available interactive online portal used to perform in-depth analyses of TCGA gene expression data (15). UALCAN can be used to determine methylation and relative expression levels, as well as the survival of a target gene across several clinopathological features. Expression levels were measured as transcripts per million. Promoter DNA methylation information was from the TCGA Infinium Human Methylation 450K BeadChip arrays. The \( t \) test was performed using a PERL script with Comprehensive Perl Archive Network module (http://search.cpan.org/~yunfang/Statistics-TTest-1.1.0/TTest.pm) to compare the statistical significance between two independent groups.

GeneMANIA analysis. GeneMANIA (http://genemania.org/) is a web interface that uses large sets of functional association data to identify single genes related to a set of input genes (16). Association data include protein and genetic interaction pathways, co-expression, co-localization and protein domain homology. GeneMANIA was used to construct the BCAT1 biological network.

LinkedOmics analysis. The LinkedOmics database (http://www.linkedomics.org/login.php) contains the multi-omics and clinical data of 32 cancer types, and a total of 11,158 patients from TCGA project (17). LinkFinder, one of three modules, was used to identify differentially expressed genes (DEGs) in TCGA LIHC cohort whose expression levels correlated with those of BCAT1. The searching and targeting datasets were both of ‘RNAseq’, and the results were statistically analyzed using Pearson’s correlation coefficient. LinkInterpreter, a module that recruited Web-based Gene SeT AnaLysis Toolkit, was used to determine the pathways and networks in which the identified DEGs were involved (18).

HCCDB analysis. The HCCDB database (http://lifeome.net/database/hccdb/home.html) comprises ~4,000 clinical samples from 15 public HCC expression datasets (13 GEO microarray datasets and two RNA-Seq datasets, TCGA-LIHC and ICGC LIRI-JP) and serves as a one-stop online resource for the investigation of HCC gene expression (19). All GEO datasets are available from the GEO repository (https://www.ncbi.nlm.nih.gov/geo). The accession numbers are: GSE25097 (20-23), GSE22058 (24-25), GSE36376 (26), GSE14520 (27-30), GSE10143 (31), GSE9843 (32-35), GSE19977 (33,34), GSE46444 (36), GSE54236 (37,38), GSE63898 (39), GSE43619 (40), GSE64041 (41) and GSE76427 (42). ICGC LIRI-JP is available on the ICGC Data Portal (https://dcc.icgc.org/projects/LIRI-JP) and TCGA-LIHC is available on TCGA (https://portal.gdc.cancer.gov/projects/TCGA-LIHC). HCCDB was used to analyze the BCAT1 co-expression networks of HCC and the corresponding adjacent tissues. The expression levels of BCAT1 in different datasets were also detected. Samples were classified into high-/low-expression groups by median expression value of BCAT1.

Results

Expression and promoter methylation levels of BCAT1 in HCC tissues. The expression levels of BCAT1 in HCC tissues were investigated using a number of datasets from TCGA. The data revealed that the mRNA expression levels of BCAT1 were significantly increased in HCC tissues compared with normal tissues (\( P<0.001 \); Fig. 1). Combined with the authors’ previous results (43), BCAT1 may serve as a novel diagnostic marker of HCC. Secondly, the level of BCAT1 promoter methylation in HCC tissues was also assessed. The data suggested the same trend as that of BCAT1 mRNA expression (Fig. 2); the higher the mRNA expression level, the lower the methylation level. Subsequently, data from 12 additional GEO datasets were analyzed (12 of the 15 datasets in the HCCDB database; three were not included because analysis results were not returned by HCCDB tools), which revealed contradictions between the results of different studies (Fig. 3). Studies including dataset 4, 6 and 8 revealed no significant differences in the mRNA expression levels of BCAT1 between HCC and adjacent normal tissues.

Effects of BCAT1 on the survival of patients with HCC. In tumors, the abnormal expression of specific genes has long been associated with overall patient survival. In the present study, two datasets from HCCDB were used to analyze the overall survival of HCC patients with high and low BCAT1 expression levels. This revealed that where the expression level of BCAT1 was not significantly different between the HCC and adjacent tissues, the overall survival of patients in the high- and low-BCAT1 expression cohorts did not differ significantly (Fig. 4A). By contrast, if the expression level of BCAT1 in HCC tissues was significantly increased compared within the adjacent tissues, patients with high BCAT1 expression levels possessed a lower overall survival probability than those with low expression levels (Fig. 4B).

Interaction network of BCAT1. A BCAT1 interaction network was constructed to identify potential interactions between BCAT1 and other cancer-associated proteins. The results showed that BCAT1 could be co-expressed with phosphoserine aminotransferase, was predicted to interact with 13 proteins, shared protein domains with its isoform BCAT2 and directly interacted with six proteins (Fig. 5). These proteins are involved in ‘metabolic pathway’, ‘amino acids biosynthesis and degradation’, ‘myc pathway’, ‘p53 signaling pathway’ and ‘other cancer-related pathways or biological processes’.

LinkedOmics online tools were then used to identify the genes that were co-expressed with BCAT1 in HCC. A volcano plot revealed that the expression of 2,970 genes negatively correlated with that of BCAT1 [green spot; false discovery rate (FDR) <0.05], while the expression of 9,077 genes positively correlated with BCAT1 (red spot; FDR <0.05; Fig. 6A). The top 50 negatively and positively correlated genes are displayed in Fig. 6B and C. These results indicate that BCAT1 serves a critical role in HCC development. Pearson's correlation coefficient analysis revealed a strong positive association between
the expression levels of BCAT1 and plasminogen activator, urokinase receptor (Pearson's correlation coefficient=0.7142; P=3.89x10^-59; Fig. 7A), RELT (Pearson's correlation coefficient=0.6708; P=7.628x10^-50; Fig. 7B), Fc fragment of IgG receptor Ic (Pearson's correlation coefficient=0.6651; P=9.94x10^-46; Fig. 7C), and a negative association with MLX interacting protein like (MLXIPL; Pearson's correlation coefficient=-0.5685; P=3.787x10^-33; Fig. 7E) and pyruvate dehydrogenase kinase 2 (PDK2; Pearson's correlation coefficient=-0.5421; P=1.001x10^-29; Fig. 7F), which are involved in 'extracellular matrix degradation', 'NF-kB pathway and immune response', 'IgG component', 'triglyceride synthesis', 'lymphoid organogenesis and thymopoiesis' and 'pyruvate dehydrogenation', respectively.

Biological process and molecular function analyses were conducted using gene set enrichment analysis, which showed that BCAT1-associated DEGs were involved in a number of biological processes and molecular functions, including 'protein activation cascade', 'respiratory burst', 'T cell activation', 'sphingolipid binding', 'MHC protein binding' and 'cytokine receptor activity' (Fig. 8). These data indicate that BCAT1 serves an important role in immune system activation, cellular responses to stimulation, metabolism and a number of other processes.

Discussion

The proliferation of cancer cells depends on extra nutrients acquired from the tumor microenvironment (44,45). BCAAs are essential for tumor growth and the progression of multiple biological pathways (46). A number of studies have revealed that the enzymes catalyzing BCAAs into their corresponding nutrients are predominantly overexpressed in cancer (7,13,47) and that BCAT1 is one of the most important enzymes involved in BCAA catabolism. The authors' previous study indicated that BCAT1 was significantly upregulated in HCC and that this was associated with poor patient prognosis (43). To further investigate the function networks of BCAT1 in HCC, bioinformatics analyses were performed using a selection of public databases to provide insights for future research into the metabolic regulation of HCC.

With a lack of appropriate markers of early stage HCC, 70-80% of patients are diagnosed at the advanced stage of disease and lose the opportunity to undergo surgery. Clinically, AFP has long been regarded as the standard for liver cancer diagnosis; however, a large number of HCC patients are AFP-negative (2), thus additional biomarkers for the early detection of HCC are required. A previous study explored the use of serum methylated BCAT1 and IKAROS family zinc finger 1 (IKZF1) for the detection of colorectal neoplasia; this revealed that for the diagnosis of colorectal cancer, the detection of BCAT1/IKZF1 DNA in the serum had a comparable sensitivity, but a higher specificity than the traditional fecal immunochemical test (48). The present study demonstrated that BCAT1 mRNA expression levels in HCC tissues were increased compared with those in normal tissues. In addition, the level of BCAT1 promoter methylation was decreased in HCC tissues compared with normal tissues as that indicated for mRNA expression levels. However, analysis of 12 datasets from different regions indicated that in some cases, the expression level of BCAT1 was not significantly different between the HCC and adjacent normal tissues. These results suggested that while BCAT1 may serve as a marker for the detection of HCC, regional variations may apply. For this reason, further large-scale, multicenter studies are required to confirm the role of BCAT1 in the prediction and diagnosis of HCC. Nonetheless, the analysis of BCAT1 expression and promoter methylation levels inpatients demonstrated its potential use as a reliable biomarker of HCC.

The abnormal expression of oncogenes is closely associated with patient survival (49,50). Overexpression of MTHFD1 predicted poorer overall survival in patients with HCC (51). Also, the expression levels of SIRT1were significantly increased in HCC and associated with poor patient survival (52). In this study, although the
majority of studies illustrated an upregulation in BCAT1 expression levels in HCC tissues (compared with adjacent tissues), selected cases presented an opposing result. Notably, further analyses within the present study indicated that patients with no significant differences in the level of BCAT1 expression between tumor and paracancerous tissues possessed a BCAT1 expression-independent survival rate. Meanwhile, patients with higher BCAT1 expression levels in HCC tissues exhibited a BCAT1-dependent survival probability. These results suggest that additional methods may be required to demonstrate the role of BCAT1 in HCC; this may include not only focusing on mRNA and protein expression, but also assessing the products of BCAT1 enzymatic reactions. BCAT1 is one of the key enzymes involved in amino acid metabolism, such that a repeatable method such as metabolomics analysis may further clarify the role of BCAT1. However, the results ultimately revealed that BCAT1 serves an important role in the survival of patients with HCC.

Tumorigenesis is a complex process with abnormal changes in protein-protein interactions and signaling pathways (53). BCAT1 was identified to be involved in the proliferation (4,54), apoptosis (55), invasion and metastasis (56) of cancer cells, and to be associated with poor prognosis in patients with various types of cancer (57,58). In addition, BCAT1 was reported to regulate mTOR signaling (59), as well as the Wnt (60) and FoxO signaling pathways (61). However, the effects of BCAT1 on other pathways and cellular functions remain unclear.

In the present study, the expression of BCAT1-associated genes was investigated and BCAT1 was found to be involved in various other signaling pathways and biological processes; to the best of our knowledge, the relationship between BCAT1 and other signaling pathways and biological processes remains unclear.
Figure 4. Effect of BCAT1 in survival of HCC. (A) Survival of patients with no significant difference of BCAT1 expression between HCC tissues and adjacent tissues. (B) Survival of patients with significant difference of BCAT1 expression between HCC tissues and adjacent tissues. BCAT1, branched chain amino acid transaminase 1; HCC, hepatocellular carcinoma.

Figure 5. Biological interaction network of BCAT1. Different colors represent diverse bioinformatics methods. BCAT1, branched chain amino acid transaminase 1.
BCAT1 and TP53 was previously unacknowledged. TP53I3 is induced by the tumor suppressor p53 and is involved in p53-mediated apoptosis (62). The present study predicted that BCAT1 may be involved in p53 signaling via its interaction with TP53I3, suggesting that BCAT1 serves a more important role in HCC than was originally hypothesized.

In addition to TP53I3, BCAT1 was predicted to interact with AADAT, TOP2A and DTYMK, which are involved in tryptophan and lysine metabolism, DNA topology state regulation and pyrimidine metabolism, respectively. These predictions indicated that BCAT1 may participate in a large number of biological functions in HCC via its potential interaction with (or regulation of) critical factors. In HCC, BCAT1 was predicted to associate with a number of critical genes including RELT, PDK2 and RORC, which regulate T-cell responses, apoptosis, the tricarboxylic acid cycle and inflammation (63-65).

However, there were limitations to the present study. First, only 371 tumor cases and 50 normal controls were employed for analysis, and a larger number of patients is required to verify the present findings. In addition, few patients at cancer stage 4, between 81 and 100 years of age and with extreme...
Figure 8. Enriched Gene Ontology annotations of BCAT1 correlated genes in hepatocellular carcinoma. (A) Biological process analysis. (B) Molecular function analysis. Dark blue and orange indicate FDR ≤0.05, light blue and orange indicate FDR >0.05. BCAT1, branched chain amino acid transaminase 1; FDR, false discovery rate.
obesity were included, which may suggest that a large number of HCC patients die prior to diagnosis. Secondly, only bioinformatics analysis results were displayed in this study. Further verification experiments, such as PCR experiments, western blot assays and co-immunoprecipitation, are necessary to verify the present results. Another limitation is that transcriptome sequencing cannot directly provide information on protein activity, which can only be verified by follow-up studies.

In conclusion, the present study provides bioinformatics evidence of the significance of BCAT1 in hepatocarcinogenesis and its potential as an early detection marker. The results indicated that the function and effects of BCAT1 in HCC are multifaceted, and that BCAT1 may be associated with immune activation, metabolic pathways and the cell cycle. Furthermore, a BCAT1 miRNA-target network was analyzed using TargetScan, demonstrating that thousands of miRNAs were predicted to interact with BCAT1 (data not shown) and providing a clear direction for future studies. More importantly, analysis results of the present study of this well-known gene indicated that the interactions between BCAT1 and numerous other critical proteins were uncharted. This will help us to determine the future research direction and draw a complete molecular network of BCAT1 participating in HCC. Also, the present study provided researchers, especially young researchers who lack experimental and bioinformatics analysis platforms, with guidance on finding directions for functional genome research.

Acknowledgements

Not applicable.

Funding

The present study was supported in part by the National Natural Science Foundation of China (grant no. 81773148), the National Key Sci-Tech Special Project of China (grant no. 2018ZX10302207), the Natural Science Foundation of Guangxi (grant no. 2018GXNSFDA138001), the Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guilin Medical University (grant no. 2018grnyc073) and the Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guangxi (grant no. 2019KY0553).

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in the TCGA repository, https://portal.gdc.cancer.gov/; the GEO repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25097, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6376, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10143, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9843, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19977, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46444, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54236, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63898, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43619, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64041, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76427); and the ICGC repository, https://dcc.icgc.org/projects/LIRI-JP.

Authors' contribution

RZY and WJL conceived, designed the research and drafted the manuscript; HFZ and WTX were responsible for the acquisition and analysis of data; HFZ and MJL analyzed and interpreted the data; RZY revised the manuscript for important intellectual content. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 594–424, 2018.
2. Villanueva A: Hepatocellular carcinoma. N Eng J Med 380: 1450–1462, 2019.
3. Dhanasekaran R, Limaye A and Cabrera R: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med 4: 19–37, 2012.
4. Thewes V, Simon R, Hlewnjak M, Schlottet M, Schroeter P, Schmidt K, Wu Y, Anzeneder T, Wang W, Windisch P, et al: The branched-chain amino acid transaminase 1 sustains growth of antieastrogen-resistant and ERalpha-negative breast cancer. Oncogene 36: 4124–4134, 2017.
5. Wang ZQ, Faddaoui A, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Guillemette C, Gobeil S, Macdonald E, et al: BCAT1 expression associates with ovarian cancer progression: Possible implications in altered disease metabolism. Oncotarget 6: 31522–31543, 2015.
6. Xu Y, Yu W, Yang T, Zhang M, Liang C, Cai X and Shao Q: Overexpression of BCAT1 is a prognostic marker in gastric cancer. Hum Pathol 75: 41–46, 2018.
7. Meyers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, Lau AN, Ji BW, Dixoit PD, Hosios AM, et al: Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353: 1161–1165, 2016.
8. Zheng YH, Hu WJ, Chen BC, Grah TH, Zhao YR, Bao HL, Zhu YF and Zhang QY: BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin. Liver Int 36: 1836–1847, 2016.
9. Xu M, Liu Q, Jia Y, Tu K, Yao Y, Liu Q and Guo C: BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma. Oncol Lett 12: 2648–2656, 2016.
10. Plejes M, Barbus S, Park YJ, Wang W, Schlottet M, Lindroth AM, Pleier SV, Bai AHC, Hara D, Piro RM, et al: BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 19: 901–908, 2013.
11. Zhou W, Feng X, Ren C, Jiang X, Liu W, Huang W, Liu Z, Li Z, Zeng L, Wang L, et al.: Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Mol Cancer 13: 2013.

12. Raffel S, Falcone M, Kniessel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, et al.: BCAT1 restricts eKg levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 551: 384-387, 2017.

13. Papathanassiou AE, Ko JH, Impriamou M, Bagnati M, Srivastava PK, Xu HA, Cucchi D, McAdoo SP, Ananieva EA, Mauro C and Behmnooras J: BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases. Nat Commun 8: 16040, 2017.

14. Wang HG, Xie R, Shen P, Huang XD, Ji GZ and Yang XZ: BCAT1 influences tumor suppressor gene expression in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 40: e55-e56, 2016.

15. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravartti BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19: 649-658, 2017.

16. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Fraser HB, Millstein J, Ferguson M, e20090, 2011.

17. Lian Q, Wang S, Zhang G, Wang D, Luo G, Tang J, Chen L and Cabo CM: Genomics Proteomics Bioinformatics 16: 269-275, 2010.

18. Vasaikar SV, Strain-P, Wang J and Zhang B: LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 46; D956-D963, 2018.

19. Wang J, Vasaikar S, Shi Z, Zhang B and Greer M: WebGestalt 2017: A more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res 45: W130-W137, 2017.

20. Liu Q, Wang S, Zhang G, Wang D, Luo G, Tang J, Chen L and Gu J: HCCDB: A database of hepatocellular carcinoma expression atlas. Genomics Proteomics Bioinformatics 16: 269-275, 2010.

21. Tung EK, Mak CK, Fatima S, Lo RC, Zhang C, Dai H, Poon RT, Gu J: HCCDB: A database of hepatocellular carcinoma expression atlas. Genomics Proteomics Bioinformatics 16: 269-275, 2010.

22. Lamb JR, Zhang C, Xie T, Wang K, Zhang B, Hao K, Chudin E, et al. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Fraser HB, Millstein J, Ferguson M, e20090, 2011.

23. Dong B, Lee JS, Park YY, Yang F, Xu G, Huang W, Finegold J and Moore DD: Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun 6: 5944, 2015.

24. Makowska Z, Boldovanova T, Adamezt D, Quagliata L, Vogt JE, Dill MT, Matter MS, Roth V, Terracciano L and Heim MH: Gene expression analysis of biopsy samples reveals critical limitations of transcription-based molecular classifications of hepatocellular carcinoma. J Pathol Clin Res 2: 80-92, 2016.

25. Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH, Chow PK and Kuznetsov VA: SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer. EBioMedicine 40: 406-421, 2019.

26. Villanueva A, Portela A, Sayols S, Battistion C, Hoshida Y, Ménendez-González J, Imbaud S, Letouzé E, Hernandez-Gea V, Corenlla H, et al.: HEPTROMIC Consortium: DNA methylation-based prognosis and epiderivatives in hepatocellular carcinoma. Hepatology 61: 1945-1956, 2015.

27. Ananieva EA and Wilkinson AC: Branched-chain amino acid metabolism and oncogenic role of miR-517a. Gastroenterology 140: 1618-1628.e1616, 2011.

28. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, Poon RT, Jia HL, Ye QH, Qin LX, et al.: Integrative genomic identification of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int 31: 1494-1504, 2011.

29. Chiang DY, Villanueva A, Shibata C, Takata A, Kojima K, Takehana K, et al.: Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginc. Oncotarget 6: 8339-8352, 2015.

30. Shi T, Kima K, April C, Canasto-Chiquique C, Chen X, Deshmukh M, Venkatesh A, Tan PS, Kobayashi M, Kumada H, Fan JB and Hoshida Y: Transcriptome profiling of archived section formalin-fixed paraffin-embedded (AS-FFFE) tissue for disease classification. PloS One 9: e86961, 2014.

31. Villanueva A, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Ménendez-González J, Imbaud S, Letouzé E, Hernández-Gea V, Corenlla H, et al.: Over-expression of BCAT1, a c-Myc target gene, restricts tumor suppression in early-stage hepatocellular carcinoma patients. Cancer Res 68: 6779-6788, 2008.

32. Shibata C, Takata A, Kojima K, Takehana K, et al.: Integrative genomics identifies Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 65: 861-869, 2016.

33. Villanueva A, Portela A, Sayols S, Battistion C, Hoshida Y, Ménendez-González J, Imbaud S, Letouzé E, Hernández-Gea V, Corenlla H, et al.: Metabolic interactions in the tumor microenvironment. Trends Cell Biol 27: 863-875, 2017.

34. Reina-Campos M, Moscat J and Diaz-Meco M: Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol 48: 40-47, 2017.

35. Ananieva EA and Wilkinson AC: Branched-chain amino acid metabolism in cancer. Curr Opin Clin Nutr Metab Care 21: 64-70, 2018.

36. Ananieva EA and Wilkinson AC: Branched-chain amino acid metabolism in cancer. Curr Opin Clin Nutr Metab Care 21: 64-70, 2018.

37. Shing F, Baddour J, Muller F, Wu CC, Wang H, Liao WT, Lan Z, Chen A, Gutschner T, Kang Y, et al.: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542: 119-123, 2017.
48. Symonds EL, Pedersen SK, Baker RT, Murray DH, Gaur S, Cole SR, Gopalsamy G, Mangira D, LaPointe LC and Young GP: A blood test for methylated BCAT1 and IKZF1 vs. a fecal immunochemical test for detection of colorectal neoplasia. Clin Transl Gastroenterol 7: e137, 2016.

49. Li Q, Pan X, Zhu D, Deng Z, Jiang R and Wang X: Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma via the miR-338-3p/PKM2 axis under hypoxic stress. Hepatology: Apr 20, 2019 (Epub ahead of print).

50. Itzel T, Spang R, Maass T, Munker S, Roessler S, Ebert MP, Schlitt HJ, Herr W, Evert M and Teufel A: Random gene sets in predicting survival of patients with hepatocellular carcinoma. J Mol Med (Berl) 97: 2019.

51. Yu H, Wang H, Xu HR, Zhang YC, Yu XB, Wu MC, Jin GZ and Cong WM: Overexpression of MTHFD1 in hepatocellular carcinoma predicts poorer survival and recurrence. Future Oncol 15: 1771-1780, 2019.

52. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.

53. Zhang L and Han J: Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function. Biochem Biophys Res Commun 486: 224-231, 2017.

54. Cho HR, Jeon H, Park CK, Park SH, Kang KM and Choi SH: BCAT1 is a new MR imaging-related biomarker for prognosis prediction in IDH1-wildtype glioblastoma patients. Sci Rep 7: 17740, 2017.

55. Cho HR, Jeon H, Park CK, Park SH, Kang KM and Choi SH: BCAT1 is a new MR imaging-related biomarker for prognosis prediction in IDH1-wildtype glioblastoma patients. Sci Rep 7: 17740, 2017.

56. Cho HR, Jeon H, Park CK, Park SH, Kang KM and Choi SH: BCAT1 is a new MR imaging-related biomarker for prognosis prediction in IDH1-wildtype glioblastoma patients. Sci Rep 7: 17740, 2017.

57. Cho HR, Jeon H, Park CK, Park SH, Kang KM and Choi SH: BCAT1 is a new MR imaging-related biomarker for prognosis prediction in IDH1-wildtype glioblastoma patients. Sci Rep 7: 17740, 2017.